TY - JOUR
T1 - Hurdles in therapy with regulatory T cells
AU - Trzonkowski, Piotr
AU - Bacchetta, Rosa
AU - Battaglia, Manuela
AU - Berglund, David
AU - Bohnenkamp, Hermann Richard
AU - Ten Brinke, Anja
AU - Bushell, Andrew
AU - Cools, Nathalie
AU - Geissler, Edward K.
AU - Gregori, Silvia
AU - Van Ham, S. Marieke
AU - Hilkens, Catharien
AU - Hutchinson, James A.
AU - Lombardi, Giovanna
AU - Madrigal, J. Alejandro
AU - Marek-Trzonkowska, Natalia
AU - Martinez-Caceres, Eva M.
AU - Roncarolo, Maria Grazia
AU - Sanchez-Ramon, Silvia
AU - Saudemont, Aurore
AU - Sawitzki, Birgit
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Ef orts to manufacture these cells have led to good manufacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Toleranceinducing Therapies-A FACTT?," which identif es hurdles hindering Treg clinical applications in Europe and provides possible solutions.
AB - Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Ef orts to manufacture these cells have led to good manufacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Toleranceinducing Therapies-A FACTT?," which identif es hurdles hindering Treg clinical applications in Europe and provides possible solutions.
U2 - 10.1126/scitranslmed.aaa7721
DO - 10.1126/scitranslmed.aaa7721
M3 - Review article
VL - 7
JO - Science Translational Medicine
JF - Science Translational Medicine
SN - 1946-6234
IS - 304
M1 - 304ps18
ER -